SK biopharm swings to profit in Q3 on strong cenobamate sales -
| 326030 Stock | 106,300 1,100 1.05% |
About 50% of Sk Biopharmaceutica's investors are presently thinking to get in. The analysis of current outlook of investing in Sk Biopharmaceuticals Co suggests that some traders are interested regarding Sk Biopharmaceutica's prospects. The current market sentiment, together with Sk Biopharmaceutica's historical and current headlines, can help investors time the market. In addition, many technical investors use Sk Biopharmaceuticals stock news signals to limit their universe of possible portfolio assets.
326030 |
SK biopharm swings to profit in Q3 on strong cenobamate sales
Read at news.google.com
 |
Sk Biopharmaceutica Fundamental Analysis
We analyze Sk Biopharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sk Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sk Biopharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Sk Biopharmaceutica is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Sk Biopharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sk Biopharmaceutica stock to make a market-neutral strategy. Peer analysis of Sk Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Sk Biopharmaceutica by comparing valuation metrics with similar companies.
Peers
Sk Biopharmaceutica Related Equities
| 302440 | SK Bioscience | 8.65 | ||||
| 207940 | Samsung Biologics | 0.62 | ||||
| 144510 | Green Cross | 0.20 | ||||
| 235980 | MedPacto | 1.06 | ||||
| 334970 | Prestige Biologics | 1.92 | ||||
| 086890 | ISU Abxis | 2.92 | ||||
| 226950 | OliX PharmaceuticalsI | 3.11 |
Complementary Tools for 326030 Stock analysis
When running Sk Biopharmaceutica's price analysis, check to measure Sk Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sk Biopharmaceutica is operating at the current time. Most of Sk Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sk Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sk Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sk Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |